摘要
从内皮祖细胞(EPC)的发现,这些骨髓来源的前体被认为是内皮修复的重要媒介。因此,在不同的CV风险情景中,EPC的水平和功能发生了变化。尽管EPC显示了重要的特征,支持该细胞子集与许多炎症和免疫网络的联系,但对实际所涉及的中介物以及这些特征的临床相关性知之甚少。全身疾病一般以血管修复失败和心血管疾病发生率增加为特征,EPC损伤起着关键作用。由于他们的免疫病因,这组疾病代表了一个宝贵的方案,以解开免疫失调与EPC功能障碍之间的联系。本文就炎症细胞因子在系统性疾病中调节EPC水平和功能的前沿领域进行综述。我们还探讨了现有免疫调节药物对抗这种情况的可能性。最后,由于维生素D作为免疫系统和心血管轴中共同介质的新兴作用,我们讨论了维生素D作为炎症介导的EPC功能障碍在全身疾病中的作用这一主题。
关键词: 内皮祖细胞,系统性疾病,系统性红斑狼疮,类风湿关节炎,血管炎,系统性硬化症,炎症,维生素D。
Current Medicinal Chemistry
Title:Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Volume: 25 Issue: 35
关键词: 内皮祖细胞,系统性疾病,系统性红斑狼疮,类风湿关节炎,血管炎,系统性硬化症,炎症,维生素D。
摘要: From the discovery of Endothelial Progenitor Cells (EPC), these bone marrowderived precursors have been placed as crucial mediators of the endothelial repair. Accordingly, altered levels and function of EPC have been found in different scenarios of CV risk. Despite the fact that EPC exhibit important characteristics which support a link of this cell subset with a number of inflammatory and immune networks, little is known on the actual mediators involved and the clinical relevance of these features. Systemic diseases are generally hallmarked by a vascular repair failure and increased cardiovascular disease occurrence, EPC impairment having a pivotal role. Because of their immunemediated etiology, this group of conditions represents an invaluable scenario to unravel the connections between immune dysregulation and EPC dysfunction. In the present review, we summarize the current knowledge regarding the cutting-edge area of the modulation of EPC levels and function by inflammatory cytokines in systemic diseases. We also address the possibility of the available immunomodulatory drugs to counteract this situation. Finally, due to the emerging role of the vitamin D as a common mediator in the immune system and the cardiovascular axis, we cover the topic of the role of vitamin D as a potential player in the inflammatory-mediated EPC dysfunction in systemic diseases.
Export Options
About this article
Cite this article as:
Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases, Current Medicinal Chemistry 2018; 25 (35) . https://dx.doi.org/10.2174/0929867324666170428110311
DOI https://dx.doi.org/10.2174/0929867324666170428110311 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Ulcerative Colitis: Pathogenesis
Current Drug Targets Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews (Discontinued) Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors
Current Drug Targets Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery